ReviewMedical oncology (Northwood, London, England)2020
Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer.
Review in Medical oncology (Northwood, London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Berberine as a Multifunctional Adjuvant in Cancer Therapy: Mechanistic Insights, Nanotechnological Strategies, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine.Pharmaceutics · 2025Article
- Cytotoxic and immunomodulatory properties of Tinospora cordifolia, Boerhaavia diffusa, Berberis aristata, and Ocimum basilicum extracts against HPV-positive cervical cancer cell line.BMC complementary medicine and therapies · 2025Article
- Berberine Inhibits Breast Cancer Stem Cell Development and Decreases Inflammation: Involvement of miRNAs and IL-6.Current developments in nutrition · 2025Article
- Berberine inhibits colorectal liver metastasis via modulation of TGF-β in a cecum transplant mouse model.European journal of medical research · 2024Article
- Plant-Derived Alkaloids as a Potential Source of Treatment for Colorectal Cancer over the Past Five Years: A Comprehensive Review.Plants (Basel, Switzerland) · 2024Review
- Cost-Utility Analysis of Berberine Chemoprevention for Colorectal Cancer After Polypectomy.Cureus · 2024Article
- Cancer Pathways Targeted by Berberine: Role of microRNAs.Current medicinal chemistry · 2024Review
- Sinapine thiocyanate exhibited anti-colorectal cancer effects by inhibiting KRT6A/S100A2 axis.Cancer biology & therapy · 2023Article
- An Updated Review on the Role of Nanoformulated Phytochemicals in Colorectal Cancer.Medicina (Kaunas, Lithuania) · 2023Review
- Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine.Journal of pharmaceutical analysis · 2022Review
- Article
- GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma.Aging · 2022Article
- Network Pharmacology and Molecular Docking on the Molecular Mechanism of Jiawei-Huang Lian-Gan Jiang Decoction in the Treatment of Colorectal Adenomas.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Berberine as a Potential Agent for the Treatment of Colorectal Cancer.Frontiers in medicine · 2022Review
- Herb and Spices in Colorectal Cancer Prevention and Treatment: A Narrative Review.Frontiers in pharmacology · 2022Review
- Identification of critical pathways and potential therapeutic targets in poorly differentiated duodenal papilla adenocarcinoma.Cancer cell international · 2021Article
- Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting mFrontiers in oncology · 2021Article
- A Scientometric Visualization Analysis for Natural Products on Cancer Research from 2008 to 2020.Frontiers in pharmacology · 2021Article
- Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies indicate that inhibiting a single signaling pathway or one single product of a gene is insufficient for the prevention and treatment of cancer. This is due to the fact that dysregulation must occur in more than 500 genes in order to produce a cancerous phenotype. Despite this evidence, available drugs used for cancer treatment focus on a single target. Meanwhile, berberine as a nutraceutical is capable of targeting various processes involved in tumor development including proliferation, invasion, angiogenesis, and metastasis. In comparison with synthetic agents, berberine is cheaper, safer, and more available. Berberine has shown anti-inflammatory properties which make it an ideal option in order to prevent inflammation-associated cancers. Colorectal cancer is one of the most common cancers all over the world and its incidence is increasing each day. Therefore, further investigations about berberine could be helpful in the discovery of novel agents for preventing and/or treating colorectal cancer. This review emphasizes the studies investigating the roles of berberine in colorectal cancer such as controlling cell signaling pathways, inducing apoptosis, regulating microRNAs, attenuating oxidative stress, and affecting inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.